Zacks spotlights Alphabet, Bank of America, Roche, Village Super Market and Aware in fresh analyst reports highlighting key ...

The firm’s current valuation of approximately DKK 790 for Zealand Pharma represents their confidence in the company’s growth prospects, particularly with the inclusion of the Roche deal for ...

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of ...

Alphabet gains on AI-driven cloud, while YouTube and Google One push subscriptions past 270M despite litigation and cloud ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.

Trans-Tasman drug developer Aft Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored ...

From sprawling department stores to luxurious day spas, we uncovered six of the best beauty hotspots in the deep south. There ...

Roche’s plan to bolster Tecentriq’s position in small cell lung cancer with Jazz Pharmaceuticals’ Zepzelca has paid off. | ...

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

New Zealand's Fonterra raised the lower end of its annual earnings forecast on Thursday, after reporting higher third-quarter ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...